RT Journal Article
SR Electronic
T1 Modeling the effectiveness of olfactory testing to limit SARS-2-CoV transmission
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20241174
DO 10.1101/2020.11.30.20241174
A1 Larremore, Daniel B.
A1 Toomre, Derek
A1 Parker, Roy
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.11.30.20241174.abstract
AB A central problem in the COVID-19 pandemic is that there is not enough testing to prevent infectious spread of SARS-CoV-2, causing surges and lockdowns with human and economic toll. Molecular tests that detect viral RNAs or antigens will be unable to rise to this challenge unless testing capacity increases by at least an order of magnitude while decreasing turnaround times. Here, we evaluate an alternative strategy based on the monitoring of olfactory dysfunction, a symptom identified in 76-83% of SARS-CoV-2 infections—including those that are otherwise asymptomatic—when a standardized olfaction test is used. We model how screening for olfactory dysfunction, with reflexive molecular tests, could be beneficial in reducing community spread of SARS-CoV-2 by varying testing frequency and the prevalence, duration, and onset time of olfactory dysfunction. We find that monitoring olfactory dysfunction could reduce spread via regular screening, and could reduce risk when used at point-of-entry for single-day events. In light of these estimated impacts, and because olfactory tests can be mass produced at low cost and self-administered, we suggest that screening for olfactory dysfunction could be a high impact and cost effective method for broad COVID-19 screening and surveillance.Competing Interest StatementD.B.L. is a member of the scientific advisory board of Darwin BioSciences. D.T. is a founder of an olfactory test company u-Smell-it LLC and has related pending patents.Funding StatementThis work was supported by the Howard Hughes Medical Institute (Roy Parker).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials, and open-source code is available at the accompanying github. https://github.com/LarremoreLab/covid_olfactory_dysfunction